Genetic Study of Mutations in Participants Previously Enrolled in NCI-99-C-0053 Who Have von Hippel-Lindau (VHL) Syndrome or Who Are at Risk for VHL Syndrome
Last Modified: 2/9/2009 First Published: 12/23/2003
Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Related Information
Registry Information
Alternate Title
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| No phase specified | Genetics | Completed | Adult | NCI-03-C-0148
NCT00075348 |
Objectives - Obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in NCI-99-C-0053 who have von Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.
- Determine genotype status in these participants.
Entry Criteria Disease Characteristics:
- Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study NCI-99-C-0053
- Meets 1 of the following criteria:
- Diagnosis of VHL syndrome
- At risk of VHL syndrome
- Family member of patient with VHL syndrome
- VHL syndrome genotype is not known
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy Endocrine therapy Radiotherapy Surgery Patient Characteristics:
Age Performance status Life expectancy Hematopoietic Hepatic Renal Expected Enrollment 260A maximum of 260 participants will be accrued for this study. Outline Participants submit a blood or buccal sample for genetic mutation analysis. Participants may receive genetic counseling and/or the results of genetic testing, if desired.
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research  | | | | William Linehan, MD, Protocol chair | | | |
Related Information PDQ® clinical trial NCI-99-C-0053 1
| Registry Information | | | Official Title | | Genetic Mutation Analysis In A VHL Population | | | Trial Start Date | | 2003-12-31 | | | Trial Completion Date | | 2008-12-23 | | | Registered in ClinicalTrials.gov | | NCT00075348 2 | | | Date Submitted to PDQ | | 2003-04-11 | | | Information Last Verified | | 2008-11-30 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.
Table of Links
| 1 | http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=67030&version=he
althprofessional |
| 2 | http://clinicaltrials.gov/ct/show/NCT00075348 |
| 
